European Pharmaceutical Review

MARCH 14, 2023

In the judgment ‘Pharmacia & Upjohn SA vs Paranova A/S’ (CJEU judgment of 12 October 1999 in case C-379/97) 2 CJEU decided that BMS conditions apply also to the medicinal product rebranding. Four recent rulings on parallel imports In November 2022, the CJEU announced four rulings on the parallel import of medicinal products.

Packaging 98

Packaging Generic Medicine Labelling Pharmaceutical Companies 98

European Pharmaceutical Review

FEBRUARY 2, 2023

This left pharmaceutical companies in Europe with no European API supply source, and only a few suppliers in Asia. When looking at the costs for labour, energy and water, companies in China and India can enjoy savings of 20 to 60 percent compared to their European competitors.

Generic Medicine 111

Generic Medicine Packaging Documentation Pharmaceutical Companies 111

Pharmaceutical Technology

DECEMBER 19, 2022

in 2022 to 1% in 2023 due to the “tightening of monetary and financial conditions”. This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. Companies relying on angel investors and venture capitalists will be most affected by an economic downturn.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceutical Companies Generic Medicine Communication 69